RCEL Stock Analysis: Buy, Sell, or Hold?
RCEL - Avita Medical, Inc. Common Stock
$4.16
-0.03 (-0.72%)
▼
5d:
-0.95%
30d:
-2.8%
90d:
-16.13%
BUY
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When RCEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RCEL shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: RCEL shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RCEL is currently trading at $4.16, which is considered oversold relative to its 30-day fair value range of $4.20 to $4.45. From a valuation perspective, the stock is trading at a discount (Forward PE: -3.6) compared to its historical average (8.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, RCEL is showing sideways momentum. Immediate support is located at $4.00, while resistance sits at $4.85.
Market Sentiment: RCEL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.21 (+73.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RCEL is showing sideways momentum. Immediate support is located at $4.00, while resistance sits at $4.85.
Market Sentiment: RCEL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.21 (+73.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.20 -
$4.45
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 73.2% below Wall St target ($7.21)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$4.20 -
$4.45
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.55
(13.3%)
Support & Resistance Levels
Support Level
$4.00
Resistance Level
$4.85
Current Trend
Sideways
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.64
Wall Street Target
$7.21
(+73.2%)
Revenue Growth (YoY)
4.0%
Profit Margin
-62.7%
PE vs Historical
-3.6 vs 8.0
CHEAP
Share & Embed Analysis
Last updated: June 03, 2026 7:59 PM ET
Data refreshes hourly during market hours. Next update: 8:59 PM
Data refreshes hourly during market hours. Next update: 8:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RCEL showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David D O'toole
BUY
3000 shares
2026-02-19
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$83 | 54 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$82 | 64 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$119 | 64 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$389 | 49 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$247 | 62 BUY |
